- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
- Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
More ▼
Key statistics
As of last trade Roche Holding AG (RHO6:FRA) traded at 28.59, 3.19% above its 52-week low of 27.70, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.59 |
---|---|
High | 28.59 |
Low | 28.59 |
Bid | 29.20 |
Offer | 29.80 |
Previous close | 29.20 |
Average volume | 119.11 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 15.77 |
Market cap | 202.90bn USD |
EPS (TTM) | 1.96 USD |
Annual div (ADY) | 1.31 EUR |
---|---|
Annual div yield (ADY) | 4.13% |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 27 2023 |
Data delayed at least 15 minutes, as of Apr 23 2024 07:13 BST.
More ▼